Analytical tools to improve decision-making during ADC development
Speed-to-clinic and then speed-to-market are highly significant metrics for companies developing biopharmaceuticals. In the article “Analytical tools to improve decision-making during antibody-drug-conjugate development” Dr Nick Hutchinson describes why it would be a mistake to underestimate the importance of optimized analytical tools for the development of biopharmaceuticals.
The recent development of a Trastuzumab-binding protein of Orla Protein Technologies illustrates this point. Development engineers in the ADC industry need a method for analysing ADC products during process development that allows the timely assessment of ADC functionality without recourse to costly cell-based methods. The Orla molecules can be used to assess functionality by testing binding of an antibody or ADC to its target and thereby enable rapid decision-making during the development process.
Read the full article by Dr Nick Hutchinson under https://knect365bioprocessing.com/2017/01/11/analytical-tools-to-improve-decision-making-during-antibody-drug-conjugate-development/